title: The use of animal models for cancer chemoprevention drug development.
abstract: Animal models currently are used to assess the efficacy of potential chemopreventive agents, including synthetic chemicals, chemical agents obtained from natural products, and natural product mixtures. The observations made in these models as well as other data are then used to prioritize agents to determine which are qualified to progress to clinical chemoprevention trials. Organ-specific animal models are employed to determine which agents or classes of agents are likely to be the most effective at nontoxic doses to prevent organ-specific forms of cancer. These results are then used to target specific organs in high-risk populations in clinical trials. The animal models used are either carcinogen-induced with carcinogens specific for particular organ sites or they are transgenic/mutant animals with insertions, deletions, or mutations at targeted gene sites known to enhance cancers in a specific organ. Animal tumor models with characteristics favorable to chemoprevention studies are available for cancers of the lung, colon, skin, bladder, mammary, prostate, head and neck, esophagus, ovary, and pancreas. In addition to single-agent dose-response testing, such models are frequently used for testing combinations of agents, testing different routes of administration, evaluating surrogate endpoint biomarkers, and generating initial pharmacokinetics and toxicology data. For some of the more standard animal models there is significant correlation with human chemopreventive trial results. There are a growing number of positive human chemoprevention trials that have used agents or combinations that were positive in animal testing. There have been fewer negative human clinical trials, but their results again correlate with negative animal results. Clearly the validation of animal models to predict the efficacy of agents in human clinical trials will await further human data on positive and negative outcomes with chemopreventive agents. Whether validated or not, animal efficacy data remain central to the clinical trial decision-making process.
authors.affiliation: Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA. vs1y@nih.gov
authors.forename: Vernon E
authors.initials: VE
authors.lastname: Steele
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Lubet
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D023041:Xenograft Model Antitumor Assays
chemical_list: D016588:Anticarcinogenic Agents
references.citation: Nat Genet. 1999 May;22(1):37-43
references.pmid: 10319859
references.citation: Oncogene. 2004 May 6;23(21):3841-50
references.pmid: 15021904
references.citation: Biometrics. 1993 Mar;49(1):259-68
references.pmid: 8513108
references.citation: Mol Cancer Ther. 2006 Jun;5(6):1530-8
references.pmid: 16818512
references.citation: Oncogene. 2004 Oct 7;23(46):7746-52
references.pmid: 15361829
references.citation: Cancer Lett. 1986 May;31(2):133-8
references.pmid: 2938725
references.citation: Cancer Res. 1976 Jul;36(7 PT 2):2626-30
references.pmid: 819130
references.citation: Cancer. 2003 Nov 1;98(9):1802-10
references.pmid: 14584060
references.citation: Basic Life Sci. 1993;61:279-89
references.pmid: 8304940
references.citation: Exp Dermatol. 2006 Sep;15(9):667-77
references.pmid: 16881963
references.citation: Gastroenterology. 2004 Sep;127(3):838-44
references.pmid: 15362039
references.citation: Crit Rev Oral Biol Med. 1990;1(3):153-66
references.pmid: 2129624
references.citation: Carcinogenesis. 2007 Feb;28(2):398-403
references.pmid: 16952912
references.citation: Cancer Res. 2006 Jul 15;66(14):7370-7
references.pmid: 16849589
references.citation: Mol Carcinog. 2005 Jul;43(3):175-81
references.pmid: 15937960
references.citation: Oral Surg Oral Med Oral Pathol. 1985 Jun;59(6):600-7
references.pmid: 3925407
references.citation: J Natl Cancer Inst. 1993 Aug 4;85(15):1220-4
references.pmid: 8331682
references.citation: Mol Cancer Ther. 2006 Apr;5(4):1073-8
references.pmid: 16648579
references.citation: Anticancer Res. 1992 Jul-Aug;12(4):1147-53
references.pmid: 1386970
references.citation: Cancer Res. 2006 Apr 15;66(8):4542-6
references.pmid: 16618783
references.citation: Carcinogenesis. 1994 Dec;15(12):2775-80
references.pmid: 8001234
references.citation: Nutr Cancer. 2000;38(1):87-97
references.pmid: 11341050
references.citation: Cancer Res. 2002 Nov 15;62(22):6506-9
references.pmid: 12438244
references.citation: Mol Carcinog. 1999 Aug;25(4):231-40
references.pmid: 10449029
references.citation: Cancer Res. 2001 Jul 1;61(13):5002-9
references.pmid: 11431333
references.citation: Cancer Res. 2000 Oct 15;60(20):5599-602
references.pmid: 11059745
references.citation: Cancer Res. 1982 Feb;42(2):508-12
references.pmid: 6459843
references.citation: Lancet Oncol. 2005 Dec;6(12):945-52
references.pmid: 16321762
references.citation: Cancer Prev Res (Phila). 2009 Nov;2(11):951-6
references.pmid: 19892664
references.citation: Cancer Res. 2004 Mar 1;64(5):1647-54
references.pmid: 14996723
references.citation: Carcinogenesis. 2007 Oct;28(10):2236-43
references.pmid: 17522065
references.citation: Carcinogenesis. 2005 Mar;26(3):571-8
references.pmid: 15591090
references.citation: Cancer Lett. 1983 Feb;18(1):69-78
references.pmid: 6218869
references.citation: Cancer Res. 2006 Sep 15;66(18):8949-53
references.pmid: 16982732
references.citation: Cancer Res. 1999 Jul 15;59(14):3387-91
references.pmid: 10416599
references.citation: Cancer Res. 1980 Feb;40(2):298-302
references.pmid: 7356512
references.citation: Cold Spring Harb Symp Quant Biol. 2005;70:225-32
references.pmid: 16869758
references.citation: Carcinogenesis. 2003 May;24(5):945-52
references.pmid: 12771040
references.citation: Anticancer Res. 1995 May-Jun;15(3):709-16
references.pmid: 7645947
references.citation: Carcinogenesis. 2001 Jan;22(1):83-8
references.pmid: 11159745
references.citation: Carcinogenesis. 2000 Feb;21(2):179-82
references.pmid: 10657955
references.citation: N Engl J Med. 2006 Aug 31;355(9):873-84
references.pmid: 16943400
references.citation: Exp Lung Res. 2000 Dec;26(8):757-72
references.pmid: 11195469
references.citation: Cancer Res. 2004 Jul 1;64(13):4385-9
references.pmid: 15231643
references.citation: Cancer Prev Res (Phila). 2009 Feb;2(2):161-7
references.pmid: 19196723
references.citation: JAMA. 2005 Jul 6;294(1):47-55
references.pmid: 15998890
references.citation: Int J Oncol. 1994 Mar;4(3):661-7
references.pmid: 21566974
references.citation: Cancer Res. 2000 Sep 15;60(18):5040-4
references.pmid: 11016626
references.citation: Prev Med. 1989 Sep;18(5):576-91
references.pmid: 2694156
references.citation: Carcinogenesis. 2006 Jun;27(6):1232-9
references.pmid: 16344269
references.citation: Breast Cancer Res Treat. 2000 Mar;60(2):117-28
references.pmid: 10845274
references.citation: Clin Cancer Res. 2004 Oct 1;10(19):6703-9
references.pmid: 15475461
references.citation: Nutr Cancer. 2007;57(2):194-200
references.pmid: 17571953
references.citation: Anticancer Res. 1994 May-Jun;14(3A):889-93
references.pmid: 8074489
references.citation: Cancer Res. 2004 Apr 1;64(7):2347-9
references.pmid: 15059884
references.citation: Int J Cancer. 2005 Feb 20;113(5):798-802
references.pmid: 15499611
references.citation: Pharmacol Ther. 1992;54(1):63-128
references.pmid: 1528955
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: Carcinogenesis. 1998 Aug;19(8):1345-51
references.pmid: 9744527
references.citation: Int J Cancer. 2010 Mar 1;126(5):1047-54
references.pmid: 19816928
references.citation: Cancer Prev Res (Phila). 2009 Feb;2(2):114-21
references.pmid: 19174584
references.citation: Cancer Res. 1997 Dec 15;57(24):5489-92
references.pmid: 9407956
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1246-52
references.pmid: 17548692
references.citation: Cancer Res. 2001 Oct 15;61(20):7449-55
references.pmid: 11606379
references.citation: Breast Cancer Res Treat. 2009 Jul;116(1):53-68
references.pmid: 18592370
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
references.pmid: 18971340
references.citation: Cancer Prev Res (Phila). 2010 Jan;3(1):73-81
references.pmid: 20051374
references.citation: J Natl Cancer Inst. 1959 Jan;22(1):19-43
references.pmid: 13621197
references.citation: Cancer Lett. 1998 Feb 13;124(1):85-93
references.pmid: 9500196
references.citation: Front Biosci. 1998 Sep 01;3:D944-60
references.pmid: 9727085
references.citation: Bull Tokyo Dent Coll. 1981 May;22(2):85-98
references.pmid: 6794920
references.citation: Exp Lung Res. 1991 Mar-Apr;17(2):485-99
references.pmid: 2050045
references.citation: Neoplasia. 2004 Sep-Oct;6(5):569-77
references.pmid: 15548366
references.citation: Biochem Biophys Res Commun. 2004 Jan 16;313(3):784-8
references.pmid: 14697260
references.citation: Carcinogenesis. 1999 Mar;20(3):425-30
references.pmid: 10190557
references.citation: Carcinogenesis. 2006 Jul;27(7):1420-31
references.pmid: 16403772
references.citation: Chem Biol Interact. 2008 Jan 30;171(2):142-51
references.pmid: 17854789
references.citation: Oncogene. 2003 Sep 18;22(40):6257-65
references.pmid: 13679864
references.citation: Carcinogenesis. 2002 Dec;23(12):2095-102
references.pmid: 12507933
references.citation: Genome Biol. 2007;8(5):R76
references.pmid: 17493263
references.citation: N Engl J Med. 2006 Aug 31;355(9):885-95
references.pmid: 16943401
references.citation: Cancer Res. 2006 Apr 15;66(8):4503-11
references.pmid: 16618778
references.citation: Carcinogenesis. 2005 Feb;26(2):441-8
references.pmid: 15591091
references.citation: J Biomed Opt. 2005 Sep-Oct;10(5):051604
references.pmid: 16292952
references.citation: Anticancer Res. 2006 Nov-Dec;26(6B):4177-83
references.pmid: 17201130